期刊文献+

代谢综合征伴心功能损害的研究及干预 被引量:1

Research and intervention in metabolic syndrome combined with cardiac function damage
原文传递
导出
摘要 代谢综合征是由肥胖、高血压、脂代谢紊乱、高血糖、胰岛素抵抗等组成的临床症候群,这些因素单独或合并存在时均可引起和加重心脏损害。研究显示,代谢综合征的总体危险性可能超过其各组分危险性的简单相加。肥胖、高血压、脂代谢紊乱、高血糖、胰岛素抵抗等通过多种机制引起心肌结构及功能的改变,其治疗应遵循综合干预和个体化原则。 Metabolic syndrome is a clinical syndrome,which includes obesity, hypertension, dyslipidemia,hyperglycemia, and insulin resistance. These components cause and aggravate the cardiac damages when exists alone or in combination. Studies showed that the overall risk of metabolic syndrome was more than the simple sum of the risk of its components. Obesity, hypertension, dyslipidemia, hyperglycemia and insulin resistance involved in the change of myocardial structure and function through several mechanisms, the treatment should follow the principle of comprehensive and individual intervention.
出处 《国际内分泌代谢杂志》 北大核心 2013年第2期132-134,共3页 International Journal of Endocrinology and Metabolism
关键词 代谢综合征 心脏功能 胰岛素抵抗 Metabolic syndrome Cardiac function Insulin resistance
  • 相关文献

参考文献20

  • 1Zhang LX. Association of metabolic syndrome with diabetes mellitus and cardiovascular disease. J Diagnostics Concepts &Practice, 2007,6 : 172-174. 被引量:1
  • 2Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome : a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute ; American Heart Association; World Heart Federation; International Atherosclerosis Society ; and International Association for the Study of Obesity. Circulation ,2009,120 : 1640-1645. 被引量:1
  • 3de Jonge LL,van Osch-Gevers L, Willemsen SP, et al. Growth, obesity, and cardiac structures in early childhood : the Generation R Study. Hypertension ,2011,57:954-940. 被引量:1
  • 4Nicaud V, Raoux S, Poirier O,et al. The TNF alpha/G-308A polymorphism influenees insulin sensitivity in offspring of patients with coronary heart disease: the European Atherosclerosis Research Study Ⅱ. Atherosclerosis,2007 ,161:317-325. 被引量:1
  • 5Iacobcllis G, Singh N, Wharton S, et al. Substantial changes in epicardial fat thickness after weight loss in severely obese subjects. Obesity ( Silver Spring ) ,2008,16 : 1693-1697. 被引量:1
  • 6Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med,2006,355:763-778. 被引量:1
  • 7卢永昕.高血压:从左室肥厚到心力衰竭[J].中华高血压杂志,2007,15(3):189-191. 被引量:49
  • 8Unger RH. Lipotoxic diseases. Annu Rev Med,2002,53:319-336. 被引量:1
  • 9Coort SL, Hasselbaink DM, Koonen DP, et al. Enhanced sarcolemmal FAT/CD36 content and triacylglycerol storage in cardiac myocytes from obese zucker rats. Diabetes,2004,53:1655-1663. 被引量:1
  • 10Gilde AJ,van der Lee KA, Willemsen PH,et al. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/deha, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res,2003,92:518-524. 被引量:1

二级参考文献26

  • 1杨慧琴,栾姝蓉,王健,唐维德,汪传意,张静,娜青.代谢综合征与左心室肥厚关系的分析[J].心肺血管病杂志,2007,26(1):33-35. 被引量:4
  • 2[1]Alan H,Fadi A.From left ventricular hypertrophy to congestive heart failure:management of hypertensive heart disease[J].Progress in Cardiovascular Disease,2006,48,326-341. 被引量:1
  • 3[2]Kiyoshi M,Koji F,Hideyuki O,et al.Role of aldosterone in left ventricular hypertrophy in hypertension[J].AJH,2006,19,13-18. 被引量:1
  • 4[3]Devereux RB,Palmieri V,Sharpe N,et al.Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based anti-hypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension:the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial[J].Circulation,2001,104:1248-1254. 被引量:1
  • 5[4]Klingbeil AU,Schneider M,Martus P,et al.A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension[J].Am J Med,2003,115:41-46. 被引量:1
  • 6[5]Arsalan S,karl T.Extracellular matrix remodeling in hypertensive heart disease[J].JACC,2006,48:1-2. 被引量:1
  • 7[6]Rubattu S,Bigatti G,Evangelista A,et al.Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension[J].JACC,2006,48,499-505. 被引量:1
  • 8[7]Taniguchi I,Kawai M,Date T,et al.Effects of spironolactone during an angiotensin Ⅱ receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy[J].Circ J,2006,70:995-1000. 被引量:1
  • 9[8]Krauser DG,Devereux RB.Ventricular hypertrophy and hypertension:Prognostic elements and implication for management[J].Herz,2006,31:305-316. 被引量:1
  • 10[9]Matsumura K,Ohtsubo T,Oniki H.Gender-related association of serum uric acid and left ventricular hypertrophy in hypertension[J].Circ J,2006,70:885-888. 被引量:1

共引文献97

同被引文献16

引证文献1

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部